RE: Rns.. all is good8 Apr 2026 15:59
I had previously indicated that the share price was unlikely to decline significantly below 45p. The entry point was executed as anticipated, and we are now observing the expected recovery.
The current market capitalisation of approximately £70 million appears undervalued, as it does not yet reflect the anticipated £40 million capital injection. This positions the company as attractively valued relative to its upcoming financial position.
I continue to see multiple investment opportunities in the stock over the coming year, particularly as clinical trials advance. The strengthened cash position provides a solid foundation and de-risks the business in the near term.
While I have trimmed the position to capitalise on other attractive opportunities in the portfolio, I intend to maintain a modest holding given the company’s robust balance sheet and secure financial runway.